Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity

Translational Research

Volumn 153, Issue 4, 2009, Pages 190-198

  Harangi, Mariann ^a   Mirdamadi, Hossein Z ^a   Seres, Ildikó ^a   Sztanek, Ferenc ^a   Molnár, Miklós ^b   Kassai, Andrea ^a   Derdák, Zoltán ^c   Illyés, László ^d   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c BROWN UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FRACTIONATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 62649094401     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.01.007     Document Type: Article

References (46)

1. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
2. Deedwania P.C., Gupta M., Stein M., Ycas J., and Gold A. IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 99 (2007) 1538-1543
3. Mason R.P. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 98 (2006) 34P-41P
4. Movva R., and Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 54 (2008) 788-800
5. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 (2003) 152-160
6. Jones P.H., Hunninghake D.B., Ferdinand K.C., et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios inpatients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 26 (2004) 1388-1399
7. Ballantyne C., Blazing M., Hunningake D., et al. Effect on high-density lipoprotein cholesterol of maximum doses of simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J 146 (2003) 862-869
8. Segrest J.P., Harvey S.C., and Zannis V. Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications. Trends Cardiovasc Med 10 (2000) 246-252
9. Tall A.R., Sammett D., Vita G.M., Deckelbaum R., and Olivecrona T. Lipoprotein lipase enhances the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from high density lipoproteins to very low density lipoproteins. J Biol Chem 259 (1984) 9587-9594
10. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., and Harmony J.A. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33 (1994) 832-839
11. La Du B.N., Adkins S., Kuo C.L., and Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 87 (1993) 25-34
12. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122 (1997) 265-268
13. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20 (2000) 516-521
14. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423 (1998) 57-60
15. La Du B.N., and Eckerson H.W. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 43 (1984) 2338-2341
16. Atmeh R.F., Shepherd J., and Packard C.J. Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. Biochim Biophys Acta 751 (1983) 175-188
17. Moren X., Deakin S.P., Liu M.L., Taskinen M.R., and James R.W. HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 49 (2008) 1246-1253
18. Guerin M., Lassel T.S., Le Goff W., Farnier M., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
19. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43 (2002) 1701-1707
20. Kawano M., Nagasaka S., Yagyu H., and Ishibashi S. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 15 (2008) 41-46
21. Schaefer E.J., McNamara J.R., Tayler T., et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 90 (2002) 689-696
22. Ai M., Otokozawa S., Asztalos B.F., et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 101 (2008) 315-318
23. O'Keefe Jr. J.H., Captain B.K., Jones P.G., and Harris W.S. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol 7 (2004) 154-160
24. Kassai A., Illyés L., Mirdamadi H.Z., et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 40 (2007) 1-5
25. Paragh G., Seres I., Balogh Z., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80 (1998) 166-170
26. Blanche P.J., Gong E.L., Forte T.M., and Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 665 (1981) 408-419
27. Singh A.T., Rainwater D.L., Haffner S.M., et al. Effect of diabetes on lipoprotein size. Arterioscler Thromb Vasc Biol 15 (1995) 1805-1811
28. Campos H., Genest Jr. J.J., Blijlevens E., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12 (1992) 187-195
29. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
30. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., and Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325 (1991) 373-381
31. Musliner T.A., and Krauss R.M. Lipoprotein subspecies and risk of coronary disease. Clin Chem 34 (1988) B78-B83
32. Levy R.I., Brensike J.F., Epstein S.E., et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 69 (1984) 325-337
33. Kempen H.J., van Gent C.M., Buytenhek R., and Buis B. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function. J Lab Clin Med 109 (1987) 19-26
34. Vekic J., Topic A., Zeljkovic A., Jelic-Ivanovic Z., and Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 40 (2007) 310-316
35. Broyles F.E., Walden C.E., Hunninghake D.B., Hill-Williams D., and Knopp R.H. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 76 (1995) 129A-135A
36. Mölgaard J., Wärjerstam-Elf S., and Olsson A.G. Efficacy and safety of simvastatin for high-risk hypercholesterolemia. Am J Cardiol 83 (1999) 1043-1048
37. Collet X., Tall A.R., Serajuddin H., et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 40 (1999) 1185-1193
38. Shimoji E., Zhang B., Fan P., and Saku K. Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis 172 (2004) 247-257
39. Lagrost L., Athias A., Herbeth B., et al. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem 271 (1996) 19058-19065
40. Huesca-Gómez C., Carreón-Torres E., Nepomuceno-Mejía T., et al. Contribution of cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase to HDL size distribution. Endocr Res 30 (2004) 403-415
41. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
42. Himbergen T.M., van Tits L.J., Voorbij H.A., de Graaf J., Stalenhoef A.F., and Roest M. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med 258 (2005) 442-449
43. Bergmeier C., Siekmeier R., and Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 50 (2004) 2309-2315
44. Paragh G., Törocsik D., Seres I., et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 20 (2004) 1321-1327
45. Harangi M., Seres I., Varga Z., et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 60 (2004) 685-691
46. Vekic J., Kotur-Stevuljevic J., Jelic-Ivanovic Z., et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37 (2007) 715-723